Growth PotentialManagement highlighted the underlying growth of the CGM market and remains optimistic about CGMs becoming the standard of care in diabetes treatment.
Market OpportunityDXCM sees significant potential for continued CGM adoption across all segments, with ample white space available in their core commercial diabetes opportunity.
Product LaunchDXCM launched the 15-day Stelo CGM for non-insulin users in the U.S., making it their first over-the-counter glucose sensor.